iQure Pharma

iQure Pharma is a globally operating US Biotech focused on developing non-opioid compounds for the treatment of Neuropathic Pain, unmet clinical need. Company assets demonstrating high commercial potential with efficacy/safety profiles better than current market leader Pregabalin. Assets are at the pre-clinical stage and are fully protected by two patent applications filed in 2019. Company Directors are a blend of life science entrepreneurs and former Roche new therapeutics senior managers. Company strategy is to develop assets to the first significant value inflexion point at which out-licensing to global pharma is planned. Secured revenue streams will include upfront payment, milestone payments and royalties.